With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity treatment scene has persuaded Zealand Pharma to aim its development engine ...
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results